Unknown

Dataset Information

0

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.


ABSTRACT: The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset of resistance in the majority of patients. Here, we show that treatment of NRAS-mutant melanoma cell lines with the MEK inhibitors AZD6244 or trametinib resulted in a rebound activation of phospho-ERK (pERK). Functionally, the recovery of signaling was associated with the maintenance of cyclin-D1 expression and therapeutic escape. The combination of a MEK inhibitor with an ERK inhibitor suppressed the recovery of cyclin-D1 expression and was associated with a significant enhancement of apoptosis and the abrogation of clonal outgrowth. The MEK/ERK combination strategy induced greater levels of apoptosis compared with dual MEK/CDK4 or MEK/PI3K inhibition across a panel of cell lines. These data provide the rationale for further investigation of vertically co-targeting the MAPK pathway as a potential treatment option for NRAS-mutant melanoma patients.

PROVIDER: S-EPMC4211982 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5601630 | BioStudies
2017-01-01 | S-EPMC5593717 | BioStudies
2016-01-01 | S-EPMC4731059 | BioStudies
| S-EPMC4005042 | BioStudies
2011-01-01 | S-EPMC3237573 | BioStudies
2014-01-01 | S-EPMC4244135 | BioStudies
| S-EPMC4515205 | BioStudies
1000-01-01 | S-EPMC3593920 | BioStudies
2007-01-01 | S-EPMC1978100 | BioStudies
2014-01-01 | S-EPMC3945937 | BioStudies